Table S1: Antibodies for Immunohistochemical Analysis of TMA

Table S1: Antibodies for Immunohistochemical analysis of TMA

Marker / Company / Clone / Dil. / Antigen retrieval / Incubation time (min) / Temp
(oC) / Assess-ment / Cut-off / Ref
ER / Ventana / SP1 / pre-diluted / EDTA pH8 / 32 / 37 / N / ≥1% / (17)
PR / Ventana / 1E2 / pre-diluted / EDTA pH8 / 32 / 37 / N / ≥1% / (17)
Chromoganin (CG) / Biogenex / LK2H10 / 1:600 / Citrate pH6 / 32 / 37 / C / ≥5%
Synaptophysin (Syn) / Ventana / SP11 / pre-diluted / EDTA pH8 / 32 / 37 / C / ≥5%
Ki67 / Ventana / 30-9 / pre-diluted / EDTA pH8 / 32 / 37 / N / >14%
HER2 / Ventana / 4B5 / pre-diluted / EDTA pH8 / 16 / 37 / M / 3+ / (18)
CK5/6 / Dako / D5/6 B4 / 1:40 / EDTA pH8 / 32 / 37 / C, M / ≥5%
CK14 / Neomarker / LL002 / 1:100 / EDTA pH8 / 32 / 37 / C, M / ≥5%
c-Kit / Dako / 104D2 / 1:300 / EDTA pH8 / 32 / 37 / C, M / ≥5%
EGFR / Ventana / 3C6 / pre-diluted / EDTA pH8 / 32 / 37 / M / ≥5%
P63 / Ventana / 4A4 / pre-diluted / EDTA pH8 / 32 / 37 / N / ≥5%

Assessment: ‘N’-nuclear; ‘C’-cytoplasmic and ‘M’-membranous staining

Table S2 Multivariate cox regression analysis of clinic-pathological parameters and the presence of fibrotic focus on disease free survival

Clinico-pathological parameters / Hazard ratio / 95% confident interval / p-value
LVI / 2.239 / 1.086-4.612 / 0.029
Lymph node involvement / 4.426 / 1.835-10.680 / 0.001
FF / 2.570 / 1.267-5.214 / 0.009
Grade / 3.024 / 1.717-5.323 / <0.001

Tumor size, age, EIC, ER and HER2 status were not statistically significant predictors of disease free survival by backward ward multivariate analysis.